ADTX Quote, Financials, Valuation and Earnings

GB Sciences, Inc. has a net margin of -3458242.86% compared to Aditxt, Inc.'s net margin of --. Aditxt, Inc.'s return on equity of -681.25% beat GB Sciences, Inc.'s return on equity of --.

Aditxt, Inc. has a consensus price target of --, signalling upside risk potential of 897058723.53%. On the other hand GB Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Aditxt, Inc. has higher upside potential than GB Sciences, Inc., analysts believe Aditxt, Inc. is more attractive than GB Sciences, Inc..

Aditxt, Inc. has a beta of 1.742, which suggesting that the stock is 74.234% more volatile than S&P 500. In comparison GB Sciences, Inc. has a beta of 11.523, suggesting its more volatile than the S&P 500 by 1052.329%.

Aditxt, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GB Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aditxt, Inc. pays -- of its earnings as a dividend. GB Sciences, Inc. pays out -- of its earnings as a dividend.

Aditxt, Inc. quarterly revenues are $700, which are larger than GB Sciences, Inc. quarterly revenues of --. Aditxt, Inc.'s net income of -$24.2M is lower than GB Sciences, Inc.'s net income of -$190.5K. Notably, Aditxt, Inc.'s price-to-earnings ratio is -- while GB Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aditxt, Inc. is 69.70x versus 1.26x for GB Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Iovance Biotherapeutics, Inc. has a net margin of -3458242.86% compared to Aditxt, Inc.'s net margin of -82.92%. Aditxt, Inc.'s return on equity of -681.25% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.64%.

Aditxt, Inc. has a consensus price target of --, signalling upside risk potential of 897058723.53%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 162.39%. Given that Aditxt, Inc. has higher upside potential than Iovance Biotherapeutics, Inc., analysts believe Aditxt, Inc. is more attractive than Iovance Biotherapeutics, Inc..

Aditxt, Inc. has a beta of 1.742, which suggesting that the stock is 74.234% more volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.49%.

Aditxt, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aditxt, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Aditxt, Inc. quarterly revenues are $700, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $86.7M. Aditxt, Inc.'s net income of -$24.2M is higher than Iovance Biotherapeutics, Inc.'s net income of -$71.9M. Notably, Aditxt, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aditxt, Inc. is 69.70x versus 4.62x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protokinetix, Inc. has a net margin of -3458242.86% compared to Aditxt, Inc.'s net margin of --. Aditxt, Inc.'s return on equity of -681.25% beat Protokinetix, Inc.'s return on equity of -111.59%.

Aditxt, Inc. has a consensus price target of --, signalling upside risk potential of 897058723.53%. On the other hand Protokinetix, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Aditxt, Inc. has higher upside potential than Protokinetix, Inc., analysts believe Aditxt, Inc. is more attractive than Protokinetix, Inc..

Aditxt, Inc. has a beta of 1.742, which suggesting that the stock is 74.234% more volatile than S&P 500. In comparison Protokinetix, Inc. has a beta of 0.655, suggesting its less volatile than the S&P 500 by 34.475%.

Aditxt, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protokinetix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aditxt, Inc. pays -- of its earnings as a dividend. Protokinetix, Inc. pays out -- of its earnings as a dividend.

Aditxt, Inc. quarterly revenues are $700, which are larger than Protokinetix, Inc. quarterly revenues of --. Aditxt, Inc.'s net income of -$24.2M is lower than Protokinetix, Inc.'s net income of -$84.9K. Notably, Aditxt, Inc.'s price-to-earnings ratio is -- while Protokinetix, Inc.'s PE ratio is 23.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aditxt, Inc. is 69.70x versus -- for Protokinetix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -3458242.86% compared to Aditxt, Inc.'s net margin of -417.92%. Aditxt, Inc.'s return on equity of -681.25% beat Plus Therapeutics, Inc.'s return on equity of --.

Aditxt, Inc. has a consensus price target of --, signalling upside risk potential of 897058723.53%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $146.88 which suggests that it could grow by 4025.7%. Given that Aditxt, Inc. has higher upside potential than Plus Therapeutics, Inc., analysts believe Aditxt, Inc. is more attractive than Plus Therapeutics, Inc..

Aditxt, Inc. has a beta of 1.742, which suggesting that the stock is 74.234% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 1.025, suggesting its more volatile than the S&P 500 by 2.509%.

Aditxt, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aditxt, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Aditxt, Inc. quarterly revenues are $700, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Aditxt, Inc.'s net income of -$24.2M is lower than Plus Therapeutics, Inc.'s net income of -$5.7M. Notably, Aditxt, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aditxt, Inc. is 69.70x versus 3.21x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.